A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Andrew Blauvelt, Joseph F Fowler, Jr., Ellen Schuck, Julia Jauch, Heike Woehling, Craig L Leonardi
Abstract Not Available
adalimumab; biosimilar; psoriasis
Abstract - 200 Poster PDF - 49
- There are currently no refbacks.